Musings from The Power List: Peng Lu
September 4, 2026
Peng Lu argues that small molecules remain indispensable as AI transforms drug development
2 min read
False
Advertisement
Development & Clinical
What Will Drug Development Look Like in 2036?
September 3, 2026
Members of The Medicine Maker’s 2026 Power List predict how AI, new modalities, integrated data, and shifting global markets will reshape the industry
7 min read
China’s Biopharma Homecoming
By James Strachan, Henry Thomas
September 1, 2026
Chinese biopharma leaders are returning from the West to build a more confident – and innovative – global industry, says Cyagen’s Lance Han
7 min read
Musings from The Power List: Christine Allen
By Christine Allen
August 28, 2026
Christine Allen believes AI will connect every stage of drug development, but only if it remains guided by human expertise
2 min read
Phase III Success Marks Milestone for Personalized Cancer Vaccines
August 26, 2026
Merck and Moderna report positive phase III results for intismeran in melanoma, as The Medicine Maker revisits how cancer vaccines work and the challenges still facing the field
7 min read
The Biggest Bottlenecks Holding Back Cell and Gene Therapy
August 24, 2026
Members of the 2026 Power List argue that manufacturing, infrastructure, reimbursement, and investment now pose the greatest challenges
9 min read
Musings from The Power List: Daniel Vitt
By Daniel Vitt
August 20, 2026
From multiple sclerosis to AI-driven discovery, Daniel Vitt reflects on the future of drug development
6 min read
The Road to Commercial-Scale iPSC Cell Therapy
August 19, 2026
Can iPSC platforms deliver consistent, commercial-scale cell therapies for large patient populations?
5 min read
The Mindset for Success in Biopharma's New Multipolar World
By Jessica Allerton, James Strachan
August 18, 2026
From collapsing legacy models to the rise of Chinese biotech, industry leaders are being forced to rethink how drugs are developed, funded, and brought to market
10 min read
Musings from The Power List: John Maher
By John Maher
August 14, 2026
John Maher discusses the scientific and practical challenges of bringing CAR T-cell therapies to patients with solid tumors
4 min read
